Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from Genentech

Lineage Cell Therapeutics Q1 Earnings Call Highlights

Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) reported first-quarter 2026 results and used its earnings call to highlight progress across its cell therapy pipeline, including its lead OpRegen program in geographic atrophy, a newly launched corneal endothelial cell program called COR1, and ongoing ma

MarketBeat

Bayer CEO Bill Anderson on diversity initiatives, new menopause drugs and taming a runaway bureaucracy

Bayer's teams run on 90-day cycles, so the clock is always ticking on delivering on their goals.

Fortune

Biotechs on the Brink: 2 Stocks With Huge Potential

BriaCell Therapeutics and Recursion Pharmaceuticals are two biotech firms that may be poised for success in 2025; risk-tolerant investors might keep an eye out.

MarketBeat

From analysis to the latest developments in health,
read the most diverse news in one place.

3 Penny Stocks With 66% to 245% Upside Potential

Investing in these penny stocks could unlock extraordinary gains, with expected returns of up to 245%. Here are three analyst-recommended stocks from in-demand industries, all with significant upside potential.

Barchart

‘A head-in-the-sand approach’: The U.S. strategic drug stockpile is inadequate for a bird flu outbreak

The U.S. stock is inadequate for a H5N1 pandemic. It’s time to ramp up solutions.

Fortune

FDA approves a drug to treat severe food allergies, including milk, eggs and nuts

Xolair is considered the first medication approved by the FDA that can help protect against severe allergic reactions brought on by accidental exposure to certain foods.

WEKU

Should Advanced Micro Devices (AMD) and NVIDIA (NVDA) Be in Your Investment Mix?

The chip industry is booming thanks to high demand, quick adoption of advanced tech, and government backing. Therefore, we delve into the fundamentals of semiconductor giants NVIDIA Corporation (NVDA) and Advanced Micro Devices (AMD) to understand if they are portfolio additions now. Read on….

StockNews.com

Read news from The Economist, FT, and more,
with one subscription

Pascal Soriot of AstraZeneca: ‘The climate crisis is a health crisis’

The man who led the drive to create a not-for-profit Covid vaccine is now focusing on the deaths caused by global heating and pollution

The Guardian - UK

Two men were consumed by Covid psychosis. Their wives say one lived and the other died because of how doctors reacted

Two men developed psychosis after becoming infected with Covid-19. One of them ultimately received treatment after his concerns were repeatedly dismissed, while the other died of a possible suicide. Now, their families are trying to raise awareness about the rare and devastating condition. Andrea Blanco reports

The Independent UK

Two men were consumed by Covid psychosis. Their wives say one lived and the other died because of how doctors reacted

The Independent UK

Cellular Reset: Inside the Scientific Pursuit of a Universal Cure

A cabal of scientists is actively trying to reset the body's cells in the hope of curing disease, with some promising early results pointing the way forward.

Inverse

Vet's lawsuit blaming antimalarial drug for psychosis tossed

A lawsuit against the maker of an anti-malarial drug blamed for causing psychotic and neurological damage in U.S. servicemembers has been thrown out

The Independent UK

The Daily Biotech Pulse: FDA Decision On Biogen Alzheimer's Drug Due In January, FDA Reviews Roche's Lymphoma Candidate, Rare Pediatric Tag For Kazia's Pediatric Brain Cancer Candidate

Here's a roundup of top developments in the biotech space over the last 24 hours:

Benzinga

Roche-AC Immune's Crenezumab Fails To Show Benefit In Sub-Set Of Alzheimer's Patients

Roche Holdings AG (OTC:RHHBY) said its Alzheimer's medicine crenezumab did not slow or prevent cognitive decline in people with a specific genetic mutation that causes early-onset disease. Crenezumab did not show a statistically significant clinical benefit in its co-primary endpoints assessing the rate of change in cognitive abilities or episodic memory function. The…

Benzinga

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

Seagen Posts Encouraging Data From Tucatinib Combo Trial In Colorectal Cancer

Seagen Inc (NASDAQ:SGEN) announced topline results from phase 2 MOUNTAINEER trial investigating Tukysa (tucatinib) in combination with trastuzumab in previously treated HER2-positive metastatic colorectal cancer (mCRC) patients. Trastuzumab is sold under the name Herceptin by Genentech, a unit of Roche Holdings AG (OTC:RHHBY). Data from this trial will form the basis of a planned supplemental…

Benzinga

Teva Pharmaceutical Shares Real-World Data Of ProAir Digihaler In Asthma Patients

Teva Pharmaceutical Industries Ltd (NYSE:TEVA) announced new study findings based on newly established clinical thresholds on short-acting beta-agonist (SABA) use and real-world usage of ProAir Digihaler (albuterol sulfate) inhalation powder. ProAir Digihaler is a breath-actuated, digital SABA inhaler with built-in flow sensors that detect, record, and store objective data. 89% (319/359) of patients…

Benzinga

The Daily Biotech Pulse: Veru Shares Up On COVID Candidate Update, FDA Approves Lilly's COVID Treatment, Latest On Sanofi-AstraZeneca RSV Vaccine

Here's a roundup of top developments in the biotech space over the last 24 hours:

Benzinga

Genentech's Tiragolumab/Tecentriq Fails On Progression Free Survival In PD-L1-High Metastatic Lung Cancer

Genentech, a unit of Roche Holdings AG (OTC: RHHBY), announced results from its Phase 3 SKYSCRAPER-01 study, evaluating tiragolumab in PD-L1-high locally advanced or metastatic non-small cell lung cancer (NSCLC).

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

Genentech's Ocrevus Shows Benefit In Disability Progression & Cognitive Decline In Multiple Sclerosis

Genentech, a member of the Roche Holdings AG (OTC:RHHBY), announced new Ocrevus (ocrelizumab) data shows a benefit on disease progression and cognitive outcomes in primary progressive multiple sclerosis (PPMS0 and secondary progressive MS (SPMS). The company noted that 75% of patients achieved no evidence of progression (NEP) in a one-year interim analysis of the…

Salon

Why Big Pharma loves Tim Scott

During the second half of 2021, Scott was the top recipient of drug campaign cash in Congress

Asharq Al-Awsat

New Cancer Immunotherapy Fails in First Roche Trial

A highly anticipated new cancer immunotherapy by Roche failed to slow the progression of an aggressive form of lung cancer, the Swiss drug maker said on Wednesday, boding ill for a range of rival drug developers working on similar compounds. The Skyscraper 2 trial was the first to produce results…

Tribune News Service

Big Pharma is betting on bigger political ambitions from Sen. Tim Scott

Sen. Tim Scott, a rising star in the Republican Party with broad popularity in his home state of South Carolina, is getting showered with drug industry money before facing voters this fall.

Benzinga

Biogen Exercises Option To Participate Developing Genentech's Bispecific Antibody, Mosunetuzumab

Biogen Inc (NASDAQ: BIIB) has

Benzinga

Genentech's Evrysdi Application Under FDA Priority Review For Use In Babies Below 2 Months

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Advanced Micro Devices

483 stories

BofA

413 stories

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.